Dalfampridine (Ampyra)


Indications for Prior Authorization:

  • Improves walking speed in patients with multiple sclerosis (MS)

Patients must meet the following criteria for the indication(s) above:

  • Prescribed by a neurologist or MS specialist, AND

  • Patient must have completed a timed 25-foot walking test and scored between 8-45 seconds (updated 25-foot walking test is required for each review), AND

  • Dose does not exceed 20mg per day

This Medication is Not Approvable for the following condition(s):

  • Any condition not listed above does not meet WHA criteria for approval


  • Adults: 10 mg orally every 12 hours (maximum daily dose: 20mg)

  • Missed doses: do not administer double or extra doses if a dose is missed


  • Inital approval is 3 months

  • Renewal after three months: for 12 months if patient has achieved at least a 20% improvement from baseline in the timed 25-foot walking test
  • Yearly renewals: for 12 months if patient maintains 20% improvement from baseline in the timed 25-foot walking test
  • All approvals limited to a 30 day supply per fill


Last review date: March 7, 2017

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar